NCT05375604View on ClinicalTrials.gov

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

May 25, 2023

Study Completion Date

May 30, 2023

Conditions
Advanced Hepatocellular Carcinoma (HCC)Gastric Cancer Metastatic to LiverColorectal Cancer Metastatic to Liver
Interventions
DRUG

CDK-004

ASO-STAT6 exosome administered Intravenously

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

91010

City of Hope National Medical Center, Duarte

Sponsors

Lead Sponsor

Codiak BioSciences
All Listed Sponsors
lead

Codiak BioSciences

INDUSTRY